8-K: Concentra Group Reports Strong Q3, Raises FY25 Guidance

Concentra Group Holdings Parent, Inc. announced robust third-quarter 2025 financial results, including significant revenue and Adjusted EBITDA growth, alongside a raised full-year 2025 guidance and a new $100 million share repurchase program.

Summary

• Third quarter 2025 revenue increased 17.0% to $572.8 million, compared to $489.6 million in Q3 2024.
• Net income for Q3 2025 was $49.8 million, an increase of 8.9% from $45.8 million in Q3 2024.
• Adjusted EBITDA for Q3 2025 increased 17.1% to $118.9 million, up from $101.6 million in Q3 2024.
• Patient visits totaled 3,557,697 in Q3 2025, or 55,589 visits per day, representing a 9.2% increase in visits per day from Q3 2024.
• Revenue per visit increased 4.2% to $147.31 in Q3 2025, compared to $141.42 in Q3 2024.
• Full-year 2025 revenue guidance was raised to a range of $2.145 billion to $2.160 billion.
• Full-year 2025 Adjusted EBITDA guidance was raised to a range of $425 million to $430 million.
• The Board of Directors declared a cash dividend of $0.0625 per share, payable on or about December 9, 2025, to stockholders of record as of December 2, 2025.
• The Board of Directors authorized a share repurchase program to repurchase up to $100 million of the company's outstanding common stock, expiring on December 31, 2027.
• Net leverage was reduced to 3.6x at the end of Q3 2025, with targets of 3.5x or below by year-end 2025 and less than 3.0x by year-end 2026.
• The company operated 628 occupational health centers and 413 onsite health clinics as of September 30, 2025.

Sentiment

Score: 8

Explanation: The company reported strong Q3 financial results, including significant revenue and Adjusted EBITDA growth, and raised its full-year guidance. The declaration of a dividend and authorization of a share repurchase program demonstrate confidence and commitment to shareholder returns. While YTD net income decreased due to IPO-related interest expenses and operating cash flow saw a slight dip, the overall operational performance and strategic execution are positive.

Positives

• Strong Q3 2025 revenue growth of 17.0% to $572.8 million, demonstrating robust business expansion.
• Adjusted EBITDA increased 17.1% to $118.9 million in Q3 2025, indicating improved operational efficiency.
• Net income increased 8.9% to $49.8 million in Q3 2025, reflecting positive bottom-line performance.
• Raised full-year 2025 revenue guidance to $2.145 billion $2.160 billion, signaling confidence in continued growth.
• Raised full-year 2025 Adjusted EBITDA guidance to $425 million $430 million, projecting stronger profitability.
• Significant increase in patient visits per day by 9.2% in Q3 2025, highlighting strong demand for services.
• Revenue per visit increased by 4.2% to $147.31 in Q3 2025, indicating effective pricing or service mix.
• Expansion of occupational health centers to 628 and onsite health clinics to 413, reflecting successful inorganic and organic growth strategies.
• Net leverage reduced to 3.6x, with a target of 3.5x or below by year-end 2025 and less than 3.0x by year-end 2026, improving financial stability.
• Declaration of a cash dividend of $0.0625 per share, returning value to shareholders.
• Authorization of a $100 million share repurchase program, signaling management's belief in the company's value.
• Revolving credit facility completely paid down, with $50 million repaid in Q3 and an additional $35 million in October, enhancing liquidity.
• Nova and Pivot Onsite integrations are progressing smoothly and are largely complete, indicating successful M&A execution.
• Growing pipeline of bolt-on M&A opportunities and de novo locations for future expansion.

Negatives

• Net income for the nine months ended September 30, 2025, decreased by 8.3% to $136.7 million compared to $149.1 million in the prior year, primarily due to higher interest expense from the IPO recapitalization.
• Cash flows provided by operating activities in Q3 2025 decreased to $60.6 million from $65.9 million in Q3 2024, driven by a $25.0 million increase in interest payments.
• Net income margin for Q3 2025 decreased to 8.7% from 9.3% in Q3 2024.
• Net income margin for YTD 2025 decreased to 8.4% from 10.4% in YTD 2024.
• Adjusted EBITDA margin for YTD 2025 decreased to 20.7% from 20.9% in YTD 2024, largely due to one-time Nova/Pivot transition costs, reversal of accruals in prior year, and incremental separation costs.
• Consumer health patient visits decreased by 2.2% for the nine months ended September 30, 2025.

Risks

• The frequency of work-related injuries and illnesses.
• Adverse changes to relationships with employer customers, third-party payors, workers' compensation provider networks, or employer services networks.
• Changes to regulations, new interpretations of existing regulations, or violations of regulations.
• State fee schedule changes undertaken by state workers' compensation boards or commissions and other third-party payors.
• Ability to realize reimbursement increases at rates sufficient to keep pace with the inflation of costs.
• Labor shortages, increased employee turnover or costs, and union activity could significantly increase operating costs.
• Ability to compete effectively with other occupational health centers, onsite health clinics at employer worksites, and healthcare providers.
• A security breach of the company's, or its third-party vendors', information technology systems which may cause a violation of HIPAA and subject the company to potential legal and reputational harm.
• Negative publicity which can result in increased governmental and regulatory scrutiny and possibly adverse regulatory changes.
• Significant legal actions could subject the company to substantial uninsured liabilities.
• Litigation and other legal and regulatory proceedings in the course of business that could adversely affect business and financial statements.
• Insurance coverage may not be sufficient to cover losses the company may incur.
• Acquisitions may use significant resources, may be unsuccessful, and could expose the company to unforeseen liabilities.
• Exposure to additional risk due to reliance on third parties in many aspects of business.
• Compliance with applicable laws regarding the corporate practice of medicine and therapy and fee-splitting.
• Facilities are subject to extensive federal and state laws and regulations relating to the privacy of individually identifiable information.
• Compliance with applicable data interoperability and information blocking rules.
• Facility licensure requirements in some states are costly and time-consuming, limiting or delaying operations.
• Ability to adequately protect and enforce intellectual property and other proprietary rights.
• Adverse economic conditions in the U.S. or globally.
• Any negative impact on the global economy and capital markets resulting from other geopolitical tensions.
• The impact of impairment of goodwill and other intangible assets.
• Ability to maintain satisfactory credit ratings.
• The effects of the Separation on the business.
• Ability to achieve the expected benefits of and successfully execute the Separation and related transactions.
• Restrictions on business, potential tax and indemnification liabilities, and substantial charges in connection with the Separation and related transactions.
• The negative impact of public threats such as a global pandemic or widespread outbreak of an infectious disease similar to the COVID-19 pandemic.
• The loss of key members of the management team.
• Ability to attract and retain talented, highly skilled employees and a diverse workforce, and on the succession of senior management.
• Climate change, or legal, regulatory or market measures to address climate change.
• Increasing scrutiny and rapidly evolving expectations from stakeholders regarding ESG matters.
• Changes in tax laws or exposures to additional tax liabilities.
• Changes to United States tariff and import/export regulations and the impact on global economic conditions may have a negative effect on business, financial condition and results of operations.

Future Outlook

The company raised its full-year 2025 financial guidance, now expecting revenue between $2.145 billion and $2.160 billion and Adjusted EBITDA between $425 million and $430 million. Capital expenditures are trending towards the lower end of the $80 million to $90 million range, and the company targets a net leverage ratio of 3.5x or below by the end of 2025, further aiming for less than 3.0x by the end of 2026. Long-term financial targets include mid-to-high single-digit revenue growth, 20%+ Adjusted EBITDA margin, and over 80% annual free cash flow conversion.

Management Comments

• "2025 has continued to be an excellent year for Concentra. Building on our business growth in the first half of the year, our strong third quarter results delivered year-over-year increases in revenue, net income, and Adjusted EBITDA driven by visit and rate growth, as well as executing on our inorganic strategy. Our stellar results are a direct reflection of the commitment and effort of our outstanding colleagues." Keith Newton, Chief Executive Officer of Concentra.
• "We continue to execute on our key strategic initiatives, accelerating technology investments to modernize and enhance our systems and capabilities and making substantial progress towards our full separation from Select Medical Corporation. Through our continued focus on operational discipline and clinical excellence, as well as our core M&A and de novo strategy, we are well-positioned to deliver an exceptional experience and unmatched outcomes to our patients, customers, and partners." Matt DiCanio, Concentra's President and Chief Financial Officer.

Industry Context

Concentra is the largest provider of occupational health services in the U.S. by number of locations, operating across 47 states and the District of Columbia. The strong growth in patient visits and revenue per visit suggests a healthy and expanding demand for occupational health services, potentially driven by a robust job market or increased employer focus on employee health and safety. The company's aggressive M&A and de novo strategy indicates a focus on market consolidation and organic expansion within this specialized healthcare sector, positioning it to capitalize on industry trends.

Comparison to Industry Standards

• The company is the "nations largest provider of occupational health services by number of locations," indicating a leading market position within its specialized sector.
• The TTM Adjusted EBITDA margin of 19.8% and a long-term target of 20%+ suggests strong profitability, which is competitive within the healthcare services industry.
• The target of <3.0x net leverage by the end of 2026 demonstrates a commitment to a healthy balance sheet, which is generally favorable compared to highly leveraged peers in capital-intensive or growth-oriented industries.
• The company's diverse revenue mix, with 65% from workers' compensation and 33% from employer services, coupled with minimal government payor reimbursement (<1%), provides resilience against "stroke-of-the-pen risk" often associated with government healthcare programs, differentiating it from providers heavily reliant on Medicare/Medicaid.
• Low employer customer concentration, with less than 3% of revenue from its largest employer customer, indicates a diversified customer base, reducing reliance on any single client and mitigating concentration risk, which is a positive compared to companies with high customer concentration.

Related Party Transactions

• Transition services agreement fees of $2.7 million for the three months ended September 30, 2025, and $9.9 million for the nine months ended September 30, 2025.
• Shared service fees from Select Medical Corporation and transition services agreement fees of $3.8 million for the three months ended September 30, 2024, and $11.5 million for the nine months ended September 30, 2024.
• Interest expense on related party debt of $2,691 thousand for the three months ended September 30, 2025, and $21,980 thousand for the nine months ended September 30, 2025.
• Payments on related party revolving promissory note of $480,000 thousand for the nine months ended September 30, 2025.
• Dividend to Select of $1,535,683 thousand for the nine months ended September 30, 2024.
• Contributions from Select of $11,149 thousand for the three months ended September 30, 2024, and $3,407 thousand for the nine months ended September 30, 2024.

Stakeholder Impact

• Shareholders: Positive impact due to increased revenue and Adjusted EBITDA, raised guidance, declared cash dividend, and authorized share repurchase program, indicating management's confidence and commitment to returning value.
• Employees/Clinicians: Positive impact from "outstanding colleagues" being recognized for "commitment and effort," and continued business growth potentially leading to job security and opportunities.
• Customers (Employers): Positive impact from continued execution on strategic initiatives, technology investments, and focus on operational discipline and clinical excellence, aiming to deliver "exceptional experience and unmatched outcomes."
• Patients: Positive impact from the mission of "improving the health of Americas workforce, one patient at a time," and the focus on clinical excellence and enhanced systems.
• Creditors: Positive impact from reduced net leverage to 3.6x and a target of <3.0x by end of 2026, indicating improved financial health and debt repayment capacity.

Next Steps

• Host a conference call on November 7, 2025, at 9 a.m. Eastern Time to discuss Q3 financial results and business outlook.
• Pay the declared cash dividend on or about December 9, 2025.
• Continue focus on de-levering to achieve a net leverage target of 3.5x or below by the end of 2025 and less than 3.0x by the end of 2026.
• Continue execution on key strategic initiatives, including accelerating technology investments and progressing towards full separation from Select Medical Corporation.
• Finalize the de novo pipeline for 2026 and beyond.
• Execute on the authorized $100 million share repurchase program.

Key Dates

Recommendation

The company delivered robust Q3 2025 results, exceeding prior year performance in key operational and financial metrics like revenue, Adjusted EBITDA, patient visits, and revenue per visit. The decision to raise full-year 2025 guidance for both revenue and Adjusted EBITDA signals strong underlying business momentum and management confidence. Furthermore, the declaration of a cash dividend and the authorization of a $100 million share repurchase program underscore a commitment to shareholder returns and a belief that the stock is undervalued. While YTD net income was impacted by IPO-related interest expenses and operating cash flow saw a slight decrease, the company is actively de-levering, targeting a net leverage ratio below 3.0x by end of 2026, which strengthens its financial position. The successful integration of acquisitions and a growing M&A pipeline suggest continued strategic growth. These factors collectively present a compelling investment case.

Keywords

Occupational Health Services, Healthcare, Workers Compensation, Employer Services, Onsite Health Clinics, Dividend, Share Repurchase, Financial Results, Adjusted EBITDA, Revenue Growth, Net Leverage, M&A, De Novo, Concentra